Scientific Publications and Presentations

Scientific Data Presentations

TARA-002 in NMIBC

February 24, 2026

ASCO GU poster: ADVANCED-2: Interim Efficacy and Safety Data in BCG-Unresponsive Participants with High-grade Non-muscle Invasive Bladder Cancer

ASCO GU poster: Interim Safety and Tolerability of TARA-002 in Patients with BCG-Naive and Unresponsive High-grade Non-muscle Invasive Bladder Cancer in ADVANCED-2

December 3, 2025

ADVANCED-2 Cohort A Interim Data Update Poster

April 26, 2025

AUA poster: Preliminary Efficacy and Safety Results From ADVANCED-2: A Phase-2 Open-label Study of Intravesical TARA-002 In Adults With High-grade Non-muscle Invasive Bladder Cancer

December 5, 2024

SUO Poster - ADVANCED-2: Phase 2 Open-label Study to Evaluate Safety and Anti-tumor Activity of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer

November 30, 2023

SUO Poster - ADVANCED-1: Phase 1a Dose-finding, Open-label Study to Evaluate Safety and Toxicity of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer

SUO Poster - ADVANCED-2: Phase 2 Open-label Study to Evaluate Safety and Anti-tumor Activity of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer

April 28, 2023

AUA poster - ADVANCED-1 (Phase 1a/b) and ADVANCED-2 (Phase 1b/2) Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer

December 2, 2022

SUO 2022 Poster – Phase 1a/b Safety Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer

June 4, 2022

ASCO 2022 Poster – Phase 1a/b Safety Study of Intravesical Instillation of TARA-002 in Adults with High-grade Non-muscle Invasive Bladder Cancer

OK-432, predecessor therapy to TARA-002, NMIBC scientific publications available upon request*

OK-432, predecessor therapy to TARA-002, in LMs

May 12, 2022

ISSVA 2022 Poster – Retrospective Analysis of a Randomized Study and Open-Label Study to Evaluate the Safety and Efficacy of OK-432 in Patients with Lymphatic Malformations

January 2009

Smith M. et al. The Laryngoscope – Efficacy and safety of OK-432 immunotherapy of lymphatic malformations

Choline Chloride

March 2025

ASPEN 2025 Oral Presentation – THRIVE-1: A multi-center, cross-sectional, observational study to assess the prevalence of choline deficiency inpatients dependent on parenteral support

September 2024

ESPEN 2024 poster – THRIVE-1: A multi-center, cross-sectional, observational study to assess the prevalence of choline deficiency in patients dependent on parenteral support

March 26, 2022

ASPEN 2022 Poster – Retrospective Study Evaluating the Prevalence of Liver Disease in Patients Dependent on Parenteral Nutrition

July 2019

ASPEN 2019 Poster: Re-analysis of a randomized placebo (PBO) controlled trial of intravenous (IV) choline chloride for IFALD using state-of-the-art analytic and imaging methods and contemporary definition of IFALD

September-October 2001

Buchman AL. et al. Journal of Parenteral and External Nutrition – Choline deficiency causes reversible hepatic abnormalities in patients receiving parenteral nutrition: proof of a human choline requirement: a placebo-controlled trial

* Additional publications on OK-432 in non-muscle invasive bladder cancer are available upon request. Please reach out to Justine O’Malley (Justine.OMalley@protaratx.com) to learn more.